Harte Hanks, Inc.
HHSIndustrialsNASDAQConglomerates · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the industrials sector, Harte Hanks, Inc. focuses on Conglomerates services and products. Harte Hanks, Inc. operates as a customer experience company in the United States and internationally. At a $31.8M market cap, Harte Hanks, Inc. ranks as a micro-cap company within industrials. It operates through three segments: Revenue Solutions, Customer Care, and Fulfillment and Logistics.
Market Cap
$31.8M
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.77
EPS (Fwd)
—
ROE
-30.4%
ROA
-3.4%
Cash
$5.2M
Total Debt
$24.0M
Free CF
$4.5M
52W Change
16.4%
Annual Financials
Cash vs Debt
Where HHS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HHS finished 54.74% above its 150-day moving average ($2.74) and 49.30% above its 200-day moving average ($2.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HHS overbought or oversold?
At the September 3, 2026 close, HHS's RSI(14) was 73.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HHS has $5.2M in cash with $24.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $4.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -30.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $206.3M (2022) to $159.6M (2025), a 23% decline worth watching.
With a beta below 0.7, Harte Hanks, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing HHS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.